会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明授权
    • Trisubstituted 1,3,5-triazine derivatives
    • 三取代1,3,5-三嗪衍生物
    • US06774235B2
    • 2004-08-10
    • US10067383
    • 2002-02-05
    • Frederik Frans Desiré DaeyaertBart De CorteMarc René De JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald William Ludovici
    • Frederik Frans Desiré DaeyaertBart De CorteMarc René De JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald William Ludovici
    • C07D25166
    • C07D251/42C07D251/50C07D251/52C07D251/66C07D251/70C07D403/12
    • This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR4 or N; n is 0, 1, 2, 3 or 4; R1 and R2 are each independently selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each of the aforementioned C1-12alkyl groups may optionally and each individually be substituted; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3 is hydrogen, aryl, C1-6alkylcarbonyl, optionally substituted C1-6alkyl; and each R4 independently is hydroxy, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is —X—R5 or —X—Alk—R6; wherein R5 and R6 each independently are indanyl, indolyl or phenyl; each of said indanyl, indolyl or phenyl may be substituted; and X is —NR3—, —NH—NH—, —N═N—, —O—, —S —, —S(═O)— or —S(═O)2—; aryl is optionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and pharmaceutical compositions comprising them.
    • 本发明涉及配制N-氧化物的化合物,其药学上可接受的加成盐和立体化学异构形式,其中A是CH,CR 4或N; n为0,1,2,3或4; R 1和R 2各自独立地选自氢,羟基,C 1-12烷基,C 1-12烷氧基,C 1-12烷基羰基,C 1-12烷氧基羰基,芳基,氨基,单或二(C 1-12烷基)氨基,单 - 或二(C 1-12烷基)氨基羰基,其中每个上述C 1-12烷基可以任选地和各自独立地被取代; 或R 1和R 2一起可以形成吡咯烷基,哌啶基,吗啉基,叠氮基或单或二(C 1-12烷基)氨基C 1-4亚烷基; R 3是氢,芳基,C 1-6烷基羰基,任选取代的C 1-6烷基; 每个R 4独立地是羟基,卤素,C 1-6烷基,C 1-6烷氧基,氰基,氨基羰基,硝基,氨基,三卤代甲基或三卤代甲氧基; L是-X-R 5或-X-Alk-R 6; 其中R 5和R 6各自独立地为茚满基,吲哚基或苯基; 所述二氢化茚基,吲哚基或苯基中的每一个可以被取代; 并且X是-NR 3 - , - NH-NH - , - N = N - , - O - , - S - , - S(= O) - 或-S(= O) 芳基是任选取代的苯基; Het是任选取代的脂族或芳族杂环基; 用于制造用于治疗患有HIV(人类免疫缺陷病毒)感染的受试者的药物。 它还涉及作为式(I)化合物的亚组的新化合物,其制备方法和包含它们的药物组合物。
    • 16. 发明授权
    • HIV Inhibiting pyrimidine derivatives
    • HIV抑制嘧啶衍生物
    • US06440986B2
    • 2002-08-27
    • US09749181
    • 2000-12-27
    • Koenraad Jozef Lodewijk Marcel AndriesBart De CorteMarc René De JongeJan HeeresChih Yung HoMarcel August Constant JanssenPaul Adriaan Jan JanssenLucien Maria Henricus KoymansMichael Joseph KuklaDonald William LudoviciKoen Jeanne Alfons Van Aken
    • Koenraad Jozef Lodewijk Marcel AndriesBart De CorteMarc René De JongeJan HeeresChih Yung HoMarcel August Constant JanssenPaul Adriaan Jan JanssenLucien Maria Henricus KoymansMichael Joseph KuklaDonald William LudoviciKoen Jeanne Alfons Van Aken
    • C07D23928
    • C07D239/42C07D239/47C07D239/48C07D239/49C07D239/50C07D401/12
    • This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR4 or N; n is 0 to 4; Q is hydrogen or —NR1R2; R1 and R2 are selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each C1-12alkyl may optionally be substituted; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3 is hydrogen, aryl, C1-6alkylcarbonyl, optionally substituted C1-6alkyl, C1-6alkyloxycarbonyl,; and R4 is hydroxy, halo, optionally substituted C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; R5 is hydrogen or C1-4alkyl; L is optionally substituted C1-10alkyl, C3-10alkenyl, C3-10alkynyl, C3-7cycloalkyl; or L is —X1—R6 or —X2—Alk—R7 wherein R6 and R7 are optionally substituted phenyl; X1 and X2 are —NR3—, —NH—NH—, —N═N—, —O—, —S—, —S(═O)— or —S(═O)2—; Alk is C1-4alkanediyl; aryl is potionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical: for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.
    • 本发明涉及N-氧化物,其药学上可接受的加成盐和立体化学异构形式的化合物的用途,其中A是CH,CR 4或N; n为0〜4; Q是氢或-NR1R2; R1和R2选自氢,羟基,C1-12烷基,C1-12烷氧基,C1-12烷基羰基,C1-12烷氧基羰基,芳基,氨基,一或二(C1-12烷基)氨基,单或二(C1-12烷基) 其中每个C 1-12烷基可以任选被取代; 或R 1和R 2可以一起形成吡咯烷基,哌啶基,吗啉基,叠氮基或单或二(C 1-12烷基)氨基C 1-4亚烷基; R 3是氢,芳基,C 1-6烷基羰基,任选取代的C 1-6烷基,C 1-6烷氧基羰基。 R4为羟基,卤素,任选取代的C 1-6烷基,C 1-6烷氧基,氰基,氨基羰基,硝基,氨基,三卤代甲基,三卤代甲氧基; R5是氢或C1-4烷基; L是任选取代的C 1-10烷基,C 3-10烯基,C 3-10炔基,C 3-7环烷基; 或L是-X1-R6或-X2-Alk-R7,其中R6和R7是任选取代的苯基; X1和X2是-NR3-,-NH-NH-,-N = N-,-O - , - S - , - S(= O) - 或-S(= O) Alk是C1-4烷二基; 芳基是取代的苯基; Het是任选取代的脂族或芳族杂环基团:用于制造用于治疗患有HIV(人类免疫缺陷病毒)感染的受试者的药物。 它还涉及作为式(I)化合物的亚组的新化合物,其制备方法和包含它们的组合物。
    • 20. 发明授权
    • HIV replication inhibiting pyrimidines
    • HIV复制抑制嘧啶
    • US06878717B2
    • 2005-04-12
    • US09430966
    • 1999-11-01
    • Bart De CorteMarc Rene De JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald William LudoviciKoen Jeanne Alfons Van Aken
    • Bart De CorteMarc Rene De JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald William LudoviciKoen Jeanne Alfons Van Aken
    • C07D239/47A61K20060101A61K31/505A61K31/506A61K31/513A61K31/551A61K31/5513A61K31/675A61K31/715A61P31/18C07D20060101C07D239/42C07D239/46C07D239/48C07D239/50C07D239/80C07D401/12C07D403/12
    • A61K31/505A61K31/5513
    • This invention concerns the use of compounds of formula: the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=-a2-a3=a4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, substituted C1-6alkyl, or substituted C1-6alkyloxyC1-6alkylcarbonyl; each R2 independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalo-methylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3 wherein R3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; Q is hydrogen, C1-6alkyl, halo, polyhalo-C1-6alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C3-7cycloalkyl, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.
    • 本发明涉及下式化合物的用途:N-氧化物,药学上可接受的加成盐,季胺及其立体化学异构形式,其中-a 1 = -a 2 -a 3 = a < 与所连接的乙烯基形成苯基,吡啶基,嘧啶基,哒嗪基或吡嗪基; n为0〜4; 并在可能的情况下5; R 1是氢,芳基,甲酰基,C 1-6烷基羰基,C 1-6烷基,C 1-6烷氧基羰基,取代的C 1-6烷基或取代的C 1-6烷氧基C 1-6烷基羰基; 每个R 2独立地是羟基,卤素,任选取代的C 1-6烷基,C 2-6烯基或C 2-6炔基,C 3-7环烷基,C 1-6烷氧基,C 1-6烷氧基羰基,羧基,氰基,硝基,氨基,单或二( C 1-6烷基)氨基,多卤代甲基,多卤甲氧基,多卤代甲硫基,-S(= O)p R 6,-NH-S(= O)p R 6,-C(= O)R 6, NHC(= O)H,-C(= O)NHNH 2,-NHC(= O)R 6,-C(= NH)R 6或5元杂环; p为1或2; L是任选取代的C 1-10烷基,C 2-10烯基,C 2-10炔基或C 3-7环烷基; 或L是-X-R 3,其中R 3是任选取代的苯基,吡啶基,嘧啶基,吡嗪基或哒嗪基; X是-NR 1 - , - NH-NH-,-N = N-,-O-,-C(= O) - , - CHOH-,-S-,-S(= O) - 或 - S(= O)2-; Q是氢,C 1-6烷基,卤素,多卤代-C 1-6烷基或任选取代的氨基; Y表示羟基,卤素,C 3-7环烷基,任选取代的C 1-6烷基,C 2-6烯基或C 2-6炔基,C 1-6烷氧基,C 1-6烷氧基羰基,羧基,氰基,硝基,氨基,单或二(C 1-6烷基)氨基 ,多卤甲基,多卤甲氧基,多卤甲硫基,-S(= O)pR 6,-NH-S(= O)pR 6,-C(= O)R 6,-NHC(= O) -C(= O)NHNH